» Articles » PMID: 29113360

MicroRNA-488 Inhibits Chemoresistance of Ovarian Cancer Cells by Targeting Six1 and Mitochondrial Function

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Nov 9
PMID 29113360
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Dysregulation of miR-488 has been implicated in several human cancers. In this study, we aim to explore its expression and biological function in ovarian cancers. We found miR-488 expression was downregulated in ovarian cancer tissues. Using CCK8 and colony formation assay showed that miR-488 inhibited SKOV3 cell proliferation and colony formation, with downregulation of cyclin D1 and cyclin E protein. While miR-488 inhibitor promoted OVCAR3 cell growth and colony formation. Cell viability and Annexin V/PI staining showed that miR-488 downregulated cell survival and increased apoptosis rate when treated with cisplatin and paclitaxel. Further experiments using MitoTracker and JC-1 staining indicated that miR-488 regulated mitochondrial fission/fusion balance and inhibited mitochondrial membrane potential, with p-Drp1, Drp1 and Fis1 downregulation. Luciferase reporter assay showed that Six1 is a target of miR-488. We also found a negative association between Six1 and miR-488 in ovarian cancer tissues. In addition, Six1 overexpression induced mitochondrial fission and increased mitochondrial potential, with upregulation of Drp1 signaling. Six1 depletion showed the opposite effects. Restoration of Six1 in SKOV3 cells rescued decreased p-Drp1 and Drp1 expression induced by miR-488 mimic. Six1 plasmid also reversed the effects of miR-488 on chemoresistance and apoptosis. Taken together, the present study showed that, by targeting Six1, miR-488 inhibits chemoresistance of ovarian cancer cells through regulation of mitochondrial function.

Citing Articles

SIX1 expression and its clinicopathological significance: difference between classic and follicular variant papillary thyroid carcinoma.

Khalil E, Issa A, Kamal R Thyroid Res. 2024; 17(1):26.

PMID: 39648214 PMC: 11626750. DOI: 10.1186/s13044-024-00212-9.


Mitochondrion: Main organelle in orchestrating cancer escape from chemotherapy.

Mostafavi S, Eskandari N Cancer Rep (Hoboken). 2023; 7(2):e1942.

PMID: 38151790 PMC: 10849933. DOI: 10.1002/cnr2.1942.


Non-Coding RNA-Dependent Regulation of Mitochondrial Dynamics in Cancer Pathophysiology.

Gallo Cantafio M, Torcasio R, Viglietto G, Amodio N Noncoding RNA. 2023; 9(1).

PMID: 36827549 PMC: 9964195. DOI: 10.3390/ncrna9010016.


SHARPIN promotes cell proliferation of cholangiocarcinoma and inhibits ferroptosis via p53/SLC7A11/GPX4 signaling.

Zeng C, Lin J, Zhang K, Ou H, Shen K, Liu Q Cancer Sci. 2022; 113(11):3766-3775.

PMID: 35968603 PMC: 9633309. DOI: 10.1111/cas.15531.


Extracellular Vesicles-ceRNAs as Ovarian Cancer Biomarkers: Looking into circRNA-miRNA-mRNA Code.

Cammarata G, Barraco N, Giusti I, Gristina V, Dolo V, Taverna S Cancers (Basel). 2022; 14(14).

PMID: 35884464 PMC: 9324482. DOI: 10.3390/cancers14143404.


References
1.
He Z, Li G, Tang L, Li Y . SIX1 overexpression predicts poor prognosis and induces radioresistance through AKT signaling in esophageal squamous cell carcinoma. Onco Targets Ther. 2017; 10:1071-1079. PMC: 5328293. DOI: 10.2147/OTT.S125330. View

2.
Behbakht K, Qamar L, Aldridge C, Coletta R, Davidson S, Thorburn A . Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res. 2007; 67(7):3036-42. DOI: 10.1158/0008-5472.CAN-06-3755. View

3.
Darcy K, Birrer M . Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol. 2010; 117(3):429-39. PMC: 2877379. DOI: 10.1016/j.ygyno.2010.01.048. View

4.
Huang Q, Zhan L, Cao H, Li J, Lyu Y, Guo X . Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways. Autophagy. 2016; 12(6):999-1014. PMC: 4922447. DOI: 10.1080/15548627.2016.1166318. View

5.
Yan H, Wu W, Ge H, Li P, Wang Z . Up-Regulation of miR-204 Enhances Anoikis Sensitivity in Epithelial Ovarian Cancer Cell Line Via Brain-Derived Neurotrophic Factor Pathway In Vitro. Int J Gynecol Cancer. 2015; 25(6):944-52. DOI: 10.1097/IGC.0000000000000456. View